Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins
about
ABO-Mismatched Allogeneic Hematopoietic Stem Cell TransplantationGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Blood disorders typically associated with renal transplantationGuidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Transfusion strategies in patients undergoing stem-cell transplantation.Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange.Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation.Transfusion support issues in hematopoietic stem cell transplantation.Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation.Higher Anti-A/B isoagglutinin titers of IgG class, but not of IgM, are associated with increased red blood cell transfusion requirements in bone marrow transplantation with major ABO-mismatch.Efficacy of plasmapheresis for the treatment of pure red blood cell aplasia after allogeneic stem cell transplantation.Major ABO-incompatible BMT: isohemagglutinin reduction with plasma exchange is safe and avoids graft manipulation.
P2860
Q26750395-E506E2FC-A293-4797-9174-2C78A53A176EQ30276550-35E1CC9B-44C1-486E-9054-29738C6B4E8AQ33421793-CD0AE97E-AF78-4476-BD0C-3E7C312E1A51Q34122035-7735285D-AB97-472F-A4B3-403FE254CA62Q37865548-B58891EF-E2B5-429B-BF75-9EC38BF3BD94Q37919167-BB1C4A59-765C-464D-B955-3F5482D8E1BAQ37928443-D980F105-4A38-4B35-A6A2-1037FF94B1E3Q38287605-7FBA5764-3F17-4465-A040-896C67D50D49Q47896401-2A5EB35B-E044-41B6-BCA5-5D300F61EB2CQ48277197-EFF91769-D181-41E5-9E5E-542E68495A8DQ50436686-E2125728-3674-44E6-A47D-169D96767C82Q50496576-7FB54784-5CDC-4875-BB69-C4E3840DE39A
P2860
Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prevention of pure red cell ap ...... host anti-donor isoagglutinins
@en
Prevention of pure red cell ap ...... ost anti-donor isoagglutinins.
@nl
type
label
Prevention of pure red cell ap ...... host anti-donor isoagglutinins
@en
Prevention of pure red cell ap ...... ost anti-donor isoagglutinins.
@nl
prefLabel
Prevention of pure red cell ap ...... host anti-donor isoagglutinins
@en
Prevention of pure red cell ap ...... ost anti-donor isoagglutinins.
@nl
P2093
P2860
P356
P1433
P1476
Prevention of pure red cell ap ...... host anti-donor isoagglutinins
@en
P2093
Eveline Bucheli
Georg Stussi
Jörg D Seebach
Jörg Halter
Lutz Seebach
Piero V Valli
Urs Schanz
P2860
P304
P356
10.3324/HAEMATOL.13356
P577
2009-01-14T00:00:00Z